Etagen Pharma, Cambridge, Mass.
Etagen Pharma has developed a single-component gene editing system that capitalizes on the cell's error-free repair machinery, and uses no foreign proteins. That means it can be dosed repeatedly for more shots on goal, with a lower chance of causing an immune response than standard techniques.
The technology employs only chemically modified oligomers - dubbed Etamers - encoding wild-type versions of mutated genes,